MOG-antibody-associated hypertrophic pachymeningitis
| Autor: | Athanasios Papathanasiou, Miles Humberstone, Akram A. Hosseini, Jing-Ming Yeo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pathology
medicine.medical_specialty Unusual case biology business.industry Multiple sclerosis Generalised seizure General Medicine medicine.disease Progressive cognitive decline nervous system diseases Myelin oligodendrocyte glycoprotein 03 medical and health sciences 0302 clinical medicine Cerebrospinal fluid nervous system Neurology biology.protein medicine Brain magnetic resonance imaging 030212 general & internal medicine Neurology (clinical) Antibody business 030217 neurology & neurosurgery |
| Zdroj: | Multiple Sclerosis and Related Disorders. 42:102074 |
| ISSN: | 2211-0348 |
| DOI: | 10.1016/j.msard.2020.102074 |
| Popis: | Background The clinical spectrum of myelin oligodendrocyte glycoprotein (MOG)-antibody-associated disease is expanding. Objective To describe an unusual case of MOG-antibody-associated hypertrophic pachymeningitis (HP). Methods Case study. Results A 57-year-old female presented with a generalised seizure on a background of 3 months history of progressive cognitive decline and behavioural changes. Brain Magnetic Resonance Imaging (MRI) revealed widespread pachymeningeal enhancement and hyperintense signal in both hippocampi. Cerebrospinal Fluid (CSF) examination was normal. The patient was found positive for MOG-antibody. She clinically improved with steroids and the MRI abnormalities completely resolved. Conclusions Clinicians might consider testing for MOG-antibody in cases with HP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect